Skip to main content
. 2021 Dec 7;11:740427. doi: 10.3389/fonc.2021.740427

Figure 1.

Figure 1

Comparison of TMB, TCR D50, and percentages of CD3+, CD8+, and PD1+CD8+ T cells in pre-NAC tumors between groups of pCR versus non-pCR. (A) Average TMB is higher in tumors of non-pCR patients than in pCR patients (10.6 vs. 2.3; p = 0.043), higher in tumors of non-MPR than MPR patients (12.3 vs. 3.4, p = 0.007), and higher in tumors of non-ORR than ORR patients (21.5 vs. 5.7, p = 0.001). (B) Average TCR D50 is higher in tumors of non-pCR patients than in pCR patients (2.07 vs. 0.47; p = 0.010), higher in tumors of non-MPR than MPR patients (2.20 vs. 1.08, p = 0.018), and higher in tumors of non-ORR than ORR patients (2.56 vs. 1.64, p = 0.034). (C–E) Linear correlation was observed between TMB and metrics of TCR like D50 (y = 5.587x − 0.881; r = 0.522, p = 0.013), diversity index (y = 2.098x − 3.272; r = 0.525, p = 0.012), and entropy (y = 2.195x − 6.950; r = 0.525, p = 0.014). (F) The percentages of CD3+ cells were all higher in pCR versus non-pCR patients (14.35% vs. 5.87%, p = 0.050), in MPR vs. non-MPR patients (9.27% vs. 5.98%, p = 0.041), but not significantly different between ORR versus non-ORR patients (7.94% vs. 3.94%, 0.347). (G) The percentages of CD8+ cells were higher in pCR versus non-pCR patients (2.53% vs. 0.75%, p = 0.025), numerically but not statistically higher in MPR versus non-MPR patients (1.21% vs. 0.14%, p = 0.573), and in ORR versus non-ORR patients (1.16% vs. 0.41%, p = 0.034). (H) The percentages of CD8+PD1+ cells were numerically but not statistically lower in pCR versus non-pCR patients (0.07% vs. 0.11%, p = 0.072), MPR versus non-MPR patients (0.03% vs. 0.21%, p = 0.858), and ORR versus non-ORR patients (0.13% vs. 0.007%, p = 0.229). ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001.